#3-08E. Twenty-Year Evolution: Improving Outcomes in SLE Pregnancies (Arthritis Rheumatol, 2025)

Have two decades of evolving guidelines actually translated into better pregnancy outcomes for patients with systemic lupus erythematosus (SLE)? In a comprehensive nationwide cohort study from Sweden, researchers analyzed over 1,400 SLE pregnancies between 2003 and 2022 to answer this critical clinical question. The study reveals a promising trend: while risks remain elevated compared to the general population, the rates of preterm delivery and small-for-gestational-age (SGA) births significantly declined over the study period. Crucially, this improvement coincided with a dramatic increase in the prescription of hydroxychloroquine and low-dose aspirin, suggesting a strong association between adherence to modern pharmacological guidelines and better fetal outcomes. However, when critically appraising these findings, listeners must note a significant limitation: the registry data lacked specific information on maternal disease activity and serological profiles (such as anti-Ro/SSA), which are major confounders in obstetric risk. Nevertheless, for clinicians, this paper provides robust real-world evidence reinforcing the vital importance of proactive pharmacological management—specifically the use of antimalarials and aspirin—to mitigate risks in SLE pregnancies.

Citation: Nguyen, N.V., et al. Nationwide temporal trends in adverse pregnancy outcomes and treatments in systemic lupus erythematosus pregnancy over two decades in Sweden. Arthritis & Rheumatology. 2025. DOI: 10.1002/art.70018

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.